



REQUEST FOR QUOTATION no. 89/2025/Z/FAiND2.0 **dated 30.10.2025 for CELON PHARMA SA with its registered office in Kielpin**

In connection with the implementation of the project no. 2022/ABM/05/00005 under the name **"FGF1 analog: a novel therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases"** co-financed by the Medical Research Agency, Celon Pharma S.A. invites you to submit offers.

DATE OF PUBLICATION: 30.10.2025

LOCATION: Kazuń Nowy

ANNOUNCEMENT PUBLICATION: obligatory

ORDERING PARTY: Celon Pharma SA, ul. Ogrodowa 2a, 05-092 Kielpin

OFFICIAL WEBSITE ADDRESS OF THE ORDERING PARTY

www.celonpharma.com, telephone: 22 7515933

TYPE OF THE ORDERING PARTY: Private entity

A PARTIAL TENDER ALLOWED - NO

A VARIANT TENDER ALLOWED - NO

SERVICE COMPLETION DEADLINE: no later than 27 February 2026

CONTRACT IMPLEMENTATION PERIOD: no later than 28 February 2027 (including 12 months of cell storage)

PROCEDURE

Request for quotation

CONTRACT AWARD PROCEDURE:

1. This contract award procedure is not governed by the provisions of the Act of 11 September 2019 – the Public Procurement Law.
2. This contract award procedure shall be conducted with due observance of the principles of competitiveness, openness, transparency and equal access.
3. The Ordering Party reserves the right to cancel the procedure at any stage thereof without stating the reason.
4. The Ordering Party shall inform Suppliers about any changes made by publishing relevant information on its website.
5. The Ordering Party reserves itself the right to request additional information, documents or explanations.
6. In justified cases, at any time before the expiry of the deadline for the submission of tenders, Celon Pharma S.A. may modify or supplement the content of the invitation to tender.

CELON PHARMA S.A.

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kielpin, Dział R&D: ul. Marymoncka 15, 05-152 Kazuń Nowy / Czosnów,
tel.: +48 22 751 59 33; fax: +48 22 751 74 77 e-mail: info@celonpharma.com, www.celonpharma.com

Organ rejestrowy: Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

Prezes Zarządu: Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.105.650 PLN

KRS: 0000437778, **NIP :** 118 16 42 061



7. This invitation to tender imposes no obligation on Celon Pharma S.A. to conclude a contract.
8. Due to the need to ensure continuity of research, the Ordering Party foresees the possibility of placing supplementary orders not exceeding 50% of the original contract value specified in the agreement concluded with the Contractor.

DETAILS CONCERNING THE OBJECT OF A CONTRACT:

CPV CODE: 50000000-5

Set 1

No	Subject
1.	The subject of this contract is the establishment and full qualification of a Master Cell Bank (MCB) and Working Cell Bank (WCB) in compliance with GMP standards, which will serve as a source for the preparation of a Working Cell Bank (WCB) used in the manufacturing process of the active substance (Drug Substance) of a recombinant protein intended for phase I clinical trials. The scope of the contract includes: qualified transfer of starting material (RCB) to a GMP facility; preparation of a Master Cell Bank (MCB); optional preparation of a Working Cell Bank (WCB) from the MCB produced; performance of control and validation tests required for cell banks in accordance with ICH Q5D; development of complete documentation in accordance with GMP requirements. Strain and plasmid The client shall provide the contractor with data on the E. coli strain and plasmids comprising the expression system, together with the RCB (Research Cell Bank) used for development work. <i>The detailed description of the subject of the request for proposal is included in Att. No. 2 to this procedure – it must be completed and submitted together with the offer.</i>

Equivalent Products

1. Due to the continuation of research work as part of the said project, its specificity and unique nature, and the fact that reagents/materials used in the research process will have a significant impact on the shape of the conducted R&D work, for technical reasons of an objective nature, the description of the object of a contract indicates the reference number of the product(s).
2. Due to the uniqueness, unprecedented nature and precisely defined methodology of the conducted projects, research and experiments, as well as the necessity to maintain the continuity and repeatability of studies conducted by the Ordering Party, each Supplier offering products equivalent to the products described in the request for quotation shall be obliged:

CELON PHARMA S.A.

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kielpin, Dział R&D: ul. Marymoncka 15, 05-152 Kazuń Nowy / Czosnów,
tel.: +48 22 751 59 33; fax: +48 22 751 74 77 e-mail: info@celonpharma.com, www.celonpharma.com

Organ rejestrowy: Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

Prezes Zarządu: Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.105.650 PLN

KRS: 0000437778, **NIP :** 118 16 42 061



- to prove, on the basis of technical documentation/safety data sheets for reagents etc., and a written declaration, that the offered equivalent products (each of such products separately) meet the requirements allowing the continuation of research by the Purchaser with no need to perform additional activities (procedures), including, for example, calibration of devices or validation of the developed laboratory methods,
- to prove (by way of a written declaration included in the submitted tender) that the offered equivalent products will not cause any increase in costs due to the need to purchase additional products and other consumables,
- to assume liability – in the form of a written declaration – for any damage to equipment caused due to the use of the equivalent products offered and delivered, according to the opinion issued by an authorised repairer of the equipment manufacturer.

3. The Supplier shall pay contractual penalties to the Ordering Party:

- for any delay in the delivery of the object of a contract, for each started day of such delay, unless the delay is caused due to the Purchaser's fault,
- if the results of studies conducted with the use of the equivalent product do not satisfy the expectations,
- the Supplier expresses its consent to contractual penalties being deducted directly from the invoice amount at the time of payment of the VAT invoice related to the completion of the delivery.

TENDER EVALUATION CRITERIA:

Criterion	Weight [%]	Points	Evaluation formula
Price	100%	100	$C = \frac{\text{Lowest quoted price}}{\text{Quoted price}} \times 100 \text{ points}$

The total number of points awarded to a given tender shall be calculated according to the following formula:

$$L = C$$

where:

- **L** – total number of points,
- **C** – points awarded under the "Price" criterion.

CELON PHARMA S.A.

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kielpin, Dział R&D: ul. Marymoncka 15, 05-152 Kazuń Nowy / Czosnów,
tel.: +48 22 751 59 33; fax: +48 22 751 74 77 e-mail: info@celonpharma.com, www.celonpharma.com

Organ rejestrowy: Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

Prezes Zarządu: Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.105.650 PLN

KRS: 0000437778, **NIP :** 118 16 42 061



Address and deadline for the submission of tenders:

1. Tenders must be submitted to the Ordering Party to the address of its registered office: ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland, if sent by traditional or courier mail, or to the e-mail address: anna.zalecka@celonpharma.com, if sent by electronic mail.
2. Tenders must be submitted no later than **07.11.2025**. If a tender is sent by traditional or courier mail, it shall be considered submitted on the date it is delivered to the registered office of the Ordering Party.
3. Tenders submitted after the expiry of the deadline shall not be processed.
4. Tenders shall be evaluated at the registered office of the Ordering Party no later than **21.11.2025**.
5. Offers submitted in foreign currency shall be converted according to the exchange rate of the National Bank of Poland on the date the offers are evaluated.

Presentation of tenders:

1. Each bidder is entitled to submit only a single bid, which shall be prepared in either Polish or English
2. The offer must indicate:
 - a. the request for quotation (RFQ) number,
 - b. the date of preparation,
 - c. the bidder's details: address, telephone number, e-mail address, and tax identification number (NIP) — in the case of a foreign supplier, a relevant registration document confirming that the business activity corresponds to the subject of this request for quotation,
 - d. detailed information confirming the compliance of the proposed equipment/material with the specification,
 - e. an approximate and realistic delivery date of the goods to the Contracting Authority,
 - f. if submitted by a Bidder operating in Poland: the gross and net price, as well as the applicable tax,
 - g. if submitted by a Bidder operating outside Poland: the net offer price and a statement confirming that VAT and other taxes are not included in the quoted price. The tender must be submitted along with the "Declaration of no personal or capital connections with the Ordering Party". Att. 1
3. Together with the offer, the Bidder is required to submit a "Declaration of no personal or capital links with the Contracting Authority." The declaration constitutes Annex 1 to this request for quotation.
4. The request for quotation (RFQ) number should also appear in the subject line of any correspondence — whether sent by e-mail, traditional post, or courier.
5. The offer must remain valid for a minimum period of 30 days.
6. The payment term for any issued invoice shall be no less than 30 days.
7. The Bidder shall bear all costs related to the preparation of the offer.
8. The offer must be initialled and signed by persons authorised to represent the Contractor/Supplier.

CELON PHARMA S.A.

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kielpin, Dział R&D: ul. Marymoncka 15, 05-152 Kazuń Nowy / Czosnów,
tel.: +48 22 751 59 33; fax: +48 22 751 74 77 e-mail: info@celonpharma.com, www.celonpharma.com

Organ rejestrowy: Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

Prezes Zarządu: Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.105.650 PLN

KRS: 0000437778, **NIP :** 118 16 42 061



VII. NOTIFICATION OF THE CONTRACT AWARD

Information regarding the outcome of the contract award procedure shall be published on the Celon Pharma website.

Please Note:

1. In connection with the entry into force of the Act of April 13, 2022 on special solutions in the field of counteracting aggression against Ukraine and serving the protection of national security (Journal of Laws, item 835), entities or citizens from the Russian Federation are excluded from participation in these proceedings, while subject to the sanctions specified in Art. 1 above of the Act, provided that on the day of submitting the offer they are on the list of persons and entities against which sanction measures should be applied, kept on the website of the Public Information Bulletin of the Minister of Internal Affairs and Administration,
2. The Contracting Party reserves the right to amend the agreement concluded with the awarded tenderer as a result of the procurement for the following reasons:
 - a) justified changes in the manner of performance of the subject-matter of the order,
 - b) objective reasons beyond the control of the Contracting Party or tenderer,
 - c) changes in legal regulations in force on the day of signing the contract,
 - d) force majeure,
 - e) occurrence of another obstacle, beyond the control of the tenderer, which prevents the performance of works,
 - f) in the event of changes to the Subject of the Agreement exceeding the material and/or financial scope indicated in the Tender, the Parties undertake that such changes will be introduced by way of an amending Annex and according to the "Guidelines on the eligibility of expenditure under the European Regional Development Fund, the European Social Fund and the Cohesion Fund for 2014-2020".
3. Entities related to the Contracting Party either personally or by capital are excluded from participation in this procurement. Capital or personal relationships are understood as mutual relations between the Contracting Party or persons authorised to contract obligations on behalf of the Contracting Party or persons performing on behalf of the Contracting Party activities related to the conduct of the procedure for selecting a contractor and the contractor, consisting in particular of the following:
 - a) participation in a company as a partner in a civil law partnership or a partnership,
 - b) owning at least 10% of shares as long as the lower limit does not result from legal provisions or was not defined by IZ PO,
 - c) fulfilling the duties of member of the supervisory body or as manager, proxy or power of attorney,
 - d) being married, a direct family member, direct affinity, second-level relative or second degree affinity in lateral line or in relation to adoption, care or guardianship.
4. Each invoice issued should be due for at least 30 days.
5. Due to the necessity to maintain the continuity of tests, the Ordering Party provides for the possibility of submitting a supplementary order in the amount not exceeding 50% of the order value specified in the contract concluded with the Contractor.
6. The Ordering Party allows for the possibility of canceling the order or resigning from the order of goods and services included in the partial procedure or the entire procedure if funds are not obtained for the performance of this order or in other cases when the performance of the order will not be in the Ordering Party's best interest.
7. The Ordering Party allows for the possibility of negotiating the submitted offer.

CELON PHARMA S.A.

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kielpin, Dział R&D: ul. Marymoncka 15, 05-152 Kazuń Nowy / Czosnów,
tel.: +48 22 751 59 33; fax: +48 22 751 74 77 e-mail: info@celonpharma.com, www.celonpharma.com

Organ rejestrowy: Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

Prezes Zarządu: Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.105.650 PLN

KRS: 0000437778, **NIP :** 118 16 42 061